cas 445003-37-2|| where to buy tert-Butyl 4-bromo-2-methylbenzoate

Nom du produit:tert-Butyl 4-bromo-2-methylbenzoate

IUPAC Name:tert-butyl 4-bromo-2-methylbenzoate

Unité d'emballage	Stock disponible	Prix($)
CM154849-250mg	in stock	Ǌů
CM154849-1g	in stock	ůǵǤ
CM154849-5g	1-2 Weeks	ǵŉư
CM154849-25g	1-2 Weeks	ůǵưƓ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 445003-37-2 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:445003-37-2; Formule moléculaire:C12H15BrO2; Point de fusion:-; Code SMILES:O=C(OC(C)(C)C)C1=CC=C(Br)C=C1C; Densité:

: Numéro de catalogue:CM154849; Poids moléculaire:271.15; Point d'ébullition:; N° Mdl:MFCD08703427; Stockage:

: Benzenes; Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

: Encaleret; New England Journal of Medicine(NEJM) publication of positive encaleret proof-of-concept phase 2b results in patients with autosomal dominant hypocalcemia type 1 (ADH1).
Encaleret is an investigational, orally administered small molecule that selectively antagonizes the calcium sensing receptor (CaSR), targeting ADH1 at its source. If approved, encaleret could be the first therapy specifically indicated for the treatment of ADH1.
Encaleret has received fast track designation by the U.S. FDA and orphan drug designation in the United States and the European Union.